[go: up one dir, main page]

PE20011167A1 - Composiciones farmaceuticas que comprenden un antagonista del alfa-adrenoreceptor y un antagonista muscarinico para el tratamiento de hiperplasia prostatica benigna - Google Patents

Composiciones farmaceuticas que comprenden un antagonista del alfa-adrenoreceptor y un antagonista muscarinico para el tratamiento de hiperplasia prostatica benigna

Info

Publication number
PE20011167A1
PE20011167A1 PE2001000130A PE2001000130A PE20011167A1 PE 20011167 A1 PE20011167 A1 PE 20011167A1 PE 2001000130 A PE2001000130 A PE 2001000130A PE 2001000130 A PE2001000130 A PE 2001000130A PE 20011167 A1 PE20011167 A1 PE 20011167A1
Authority
PE
Peru
Prior art keywords
antagonist
alpha
adrenoreceptor
prostatic hyperplasia
selective
Prior art date
Application number
PE2001000130A
Other languages
English (en)
Inventor
Michael Grant Wyllie
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22663745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20011167(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20011167A1 publication Critical patent/PE20011167A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN ANTAGONISTA DEL ALFA-ADRENORRECEPTOR TAL COMO 4-AMINO-6,7-DIMETOXI-2-(5-METANOSULFONAMIDO-1,2,3,4-TETRAHIDROISOQUINOL-2-IL)-5-(2-PIRIDIL) QUINAZOLINA, DOXAZOSINA, TERAZOSINA, ABANOQUIL, PRAZOSINA, INDORAMINA Y b) UN ANTAGONISTA MUSCARINICO TAL COMO DARIFENACINA, TOLTERODINA Y OXIBUTININA. EL ANTAGONISTA DEL ALFA-ADRENORECEPTOR PUEDE SER NO SELECTIVO O SELECTIVO PARA EL RECEPTOR O-1 Y EL ANTAGONISTA MUSCARINICO PUEDE SER NO SELECTIVO O SELECTIVO PARA LOS RECEPTORES M3. LA COMPOSICION FARMACEUTICA ES UTIL PARA TRATAR LOS SINTOMAS DEL TRACTO URINARIO INFERIOR ASOCIADOS CON HIPERPLASIA PROSTATICA BENINGA (HPB)
PE2001000130A 2000-02-09 2001-02-07 Composiciones farmaceuticas que comprenden un antagonista del alfa-adrenoreceptor y un antagonista muscarinico para el tratamiento de hiperplasia prostatica benigna PE20011167A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18131000P 2000-02-09 2000-02-09

Publications (1)

Publication Number Publication Date
PE20011167A1 true PE20011167A1 (es) 2001-11-13

Family

ID=22663745

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000130A PE20011167A1 (es) 2000-02-09 2001-02-07 Composiciones farmaceuticas que comprenden un antagonista del alfa-adrenoreceptor y un antagonista muscarinico para el tratamiento de hiperplasia prostatica benigna

Country Status (12)

Country Link
US (2) US20010044438A1 (es)
EP (2) EP2266571A1 (es)
KR (2) KR20010078803A (es)
AU (3) AU1832901A (es)
CA (1) CA2334460C (es)
HU (1) HU230982B1 (es)
IL (1) IL141235A (es)
MY (1) MY164900A (es)
NZ (1) NZ509807A (es)
PE (1) PE20011167A1 (es)
TW (1) TWI287448B (es)
ZA (1) ZA200101012B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
NL1021822C2 (nl) * 2001-11-07 2003-07-15 Synthon Bv Tamsulosinetabletten.
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
EP1552825A4 (en) * 2002-06-07 2009-11-25 Astellas Pharma Inc THERAPEUTIC AGENT FOR THE TREATMENT OF VESIC HYPERACTIVITY
JP2005538139A (ja) * 2002-08-14 2005-12-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 男性および女性における過活動膀胱に関連する下部尿路症状の処置
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
AU2003207089A1 (en) * 2003-02-14 2004-09-06 Takeda Pharmaceutical Company Limited Preparation for topical administration
WO2005092341A1 (en) * 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Combination therapy for lower urinary tract symptoms
WO2005092321A1 (ja) * 2004-03-24 2005-10-06 Kissei Pharmaceutical Co., Ltd. 頻尿または尿失禁の予防または治療用医薬組成物
KR100679111B1 (ko) * 2004-11-20 2007-02-07 대우약품공업주식회사 독사조신을 포함하는 서방성 정제
WO2007010509A2 (en) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited Controlled release pharmaceutical composition comprising alpha-adrenergic antagonist and muscarinic antagonist
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
RU2008120332A (ru) * 2005-12-20 2010-01-27 Пфайзер Продактс Инк. (Us) Фармацевтическая композиция для лечения luts, содержащая ингибитор pde5 и мускариновый антагонист
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
SI2068880T1 (sl) 2006-09-18 2012-08-31 Boehringer Ingelheim Int Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
EP2172201A4 (en) * 2007-07-20 2011-07-06 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION FOR THE REDUCTION OF LOWER HARNESS SYMPTOMS RELATED TO PROSTATE GAL
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
US7891492B2 (en) * 2007-08-13 2011-02-22 Carton Service, Incorporated Pharmaceutical blister card package
EP2181707A1 (en) * 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
DK2451445T3 (da) 2009-07-06 2019-06-24 Boehringer Ingelheim Int Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
KR20150048888A (ko) * 2012-09-05 2015-05-07 체이스 파마슈티칼스 코포레이션 항콜린 신경보호 조성물 및 그 방법
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
EP3654964B1 (en) * 2017-07-20 2024-04-24 Seinda Pharmaceutical Guangzhou Corporation Composition comprising atropine and a miotic agent and its use in the treatment of myopia
KR20250112816A (ko) * 2022-11-17 2025-07-24 디알아이 바이오사이언스 코퍼레이션 신경학적 병태들의 치료 조성물 및 치료 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2503059A (en) * 1950-04-04 Nxchj
US2599000A (en) * 1950-09-02 1952-06-03 Smith Kline French Lab Nu, nu-disubstituted-beta-halo-alkylamines
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
IT1094076B (it) * 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
KR950703961A (ko) * 1992-11-04 1995-11-17 빈센트 엘. 파비아노 양성 전립선 비후증과 동맥경화증 치료방법 및 이를 위한 (+)독사조신 조성물
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6083950A (en) * 1997-11-13 2000-07-04 Ranbaxy Laboratories Limited 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers
WO2001021167A1 (en) * 1999-09-22 2001-03-29 Merck & Co., Inc. Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein

Also Published As

Publication number Publication date
US7138405B2 (en) 2006-11-21
CA2334460A1 (en) 2001-08-09
EP1123705A1 (en) 2001-08-16
AU2009227918B2 (en) 2011-09-22
HU0100586D0 (en) 2001-03-28
AU2009227918A1 (en) 2009-11-12
HUP0100586A2 (hu) 2001-11-28
US20010044438A1 (en) 2001-11-22
ZA200101012B (en) 2002-08-06
HUP0100586A3 (en) 2003-05-28
TWI287448B (en) 2007-10-01
AU2006202176A1 (en) 2006-06-15
IL141235A0 (en) 2011-08-01
US20050222165A1 (en) 2005-10-06
MY164900A (en) 2018-01-30
CA2334460C (en) 2009-01-27
HU230982B1 (hu) 2019-08-28
KR20010078803A (ko) 2001-08-21
IL141235A (en) 2012-04-30
KR20040032141A (ko) 2004-04-14
EP2266571A1 (en) 2010-12-29
NZ509807A (en) 2002-09-27
AU1832901A (en) 2001-08-16

Similar Documents

Publication Publication Date Title
PE20011167A1 (es) Composiciones farmaceuticas que comprenden un antagonista del alfa-adrenoreceptor y un antagonista muscarinico para el tratamiento de hiperplasia prostatica benigna
MA29683B1 (fr) Combinaison pour traiter une hyperplasie benigne de la prostate
ATE464304T1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonist n
WO2006029153A3 (en) Monocyclic anilide spirolactam cgrp receptor antagonists
YU60696A (sh) Dihidropirimidini i njihova primena
WO2002030462A3 (en) Hedgehog antagonists, methods and uses related thereto
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
ES2163293T3 (es) Combinacion de un inhibidor de tirosina quinasas y castracion quimica para tratar el cancer de prostata.
ATE464305T1 (de) Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
TR200200928T2 (tr) 2-pirazolin-5-on terkipleri
BRPI0413305A (pt) compostos azabicìclicos fundidos que inibem o receptor de subtipo de receptor de vanilóide 1 (vr1)
ATE447970T1 (de) Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
ATE463245T1 (de) Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
ATE537153T1 (de) Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors
ATE518852T1 (de) Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
EP1959855A4 (en) TREATMENT OF BENIGNER PROSTATE HYPERPLASIA WITH A PHOTOSENSIBILIZER AND LASER ABLATION
MX2007005428A (es) Combinaciones de agonistas del receptor nicotinico alfa 7 y de la acetilcolina.
PE20001299A1 (es) Bromhidrato de eletriptan monohidratado
ATE466853T1 (de) Cgrp-rezeptorantagonisten
AR035600A1 (es) Uso de agonistas selectivos del receptor de dopamina d4 en la fabricacion de medicamentos para tratar la disfuncion sexual
DK1000059T3 (da) Tricycliske vasopressin-agonister
DK1345907T3 (da) 7-Heterocyclyl-quinolin- og thieno-2,3-B-pyridin-derivater anvendelige som antagonister af gonadotropin-frigörende hormon
AR029482A1 (es) Sal de mesilato de 4-amino-6,7-dimetoxi-2-(5-metanosulfonamido-1,2,3,4-tetrahidroisoquinol-2-il)-5-(2-piridil) quinazolina, forma base cristalina anhidra, formulacion farmaceutica, uso en la fabricacion de medicamentos y metodo de preparacion
EA200401100A1 (ru) 1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ
BR0214611A (pt) Antagonistas vii de receptor ccr-3

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration